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BACKGROUND: There is controversy regarding the optimal management of thyroid cancer. The proportion of patients with low-risk
thyroid cancer who received radioactive iodine (RAI) treatment increased over the last 20 years, and little is known about the role
played by clinicians in hospital-level RAI use for low-risk disease. METHODS: Thyroid surgeons affiliated with 368 hospitals that had
Commission on Cancer-accredited cancer programs were surveyed. Survey data were linked to data reported to the National Cancer
Database. A multivariable analysis was used to assess the relation between clinician decision makers and hospital-level RAI use after
total thyroidectomy in patients with stage I, well differentiated thyroid cancer. RESULTS: The survey response rate was 70% (560 of
804 surgeons). The surgeon was identified as the primary decision maker by 16% of the surgeons; the endocrinologist was identified
as the primary decision maker by 69%, and a nuclear medicine, radiologist, or other physician was identified as the primary decision
maker by 15%. In a multivariable analysis controlling for hospital case volume and hospital type, when the primary decision maker was
in a specialty other than endocrinology or surgery, there was greater use of RAI at the hospital (P < .001). A greater number of pro-
viders at the hospital where RAI was administered and having access to a tumor board also were associated with increased use of
RAI (P < .001 and P ¼ .006, respectively). CONCLUSIONS: The specialty of the primary decision maker, the number of providers
administering RAI, and having access to a tumor board were associated significantly with the use of RAI for stage I thyroid cancer.
The findings have implications for addressing nonclinical variation between hospitals, with a marked heterogeneity in decision making
suggesting that standardization of care will be challenging. Cancer 2013;119:259-65.VC 2012 American Cancer Society.
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INTRODUCTION
Thyroid cancer is a common malignancy with a persistently rising incidence rate.1,2 In contrast to many other common
malignancies, there is great controversy the over standard of care for thyroid cancer.3,4 In the setting of this ongoing dis-
pute, over the last 20 years, there has been an increase in the use of radioactive iodine (RAI) after total thyroidectomy as
treatment for low-risk thyroid cancer.5,6 The benefit of using RAI to treat low-risk disease is unclear,7-10 and this increase
in the use of RAI has potential implications for patient health and health care costs. Treatment with RAI is associated with
increased risk of second primary malignancy and damage to salivary glands and lacrimal ducts.6,11,12 In addition, there are
clear cost-saving benefits when RAI is not administered to patients with low-risk disease.13
Although it is known that there is marked hospital-level variation in the use of RAI, with the most variation observed
in low-risk patients,5 the role of surgeons, endocrinologists, and nuclear medicine physicians in RAI use and in the inter-
hospital variation in its use is unknown. It is not clear whether the number and specialty of the providers involved in the
decision-making process influence the use of RAI at the hospital level.
By linking surgeon surveys to data from the National Cancer Database (NCDB), we were able to obtain details on
providers and RAI use that would not otherwise be available. The objective of the current study was to assess the role of
clinicians in hospital-level use of RAI for the treatment of patients with American Joint Committee on Cancer stage I, well
differentiated thyroid cancer.
MATERIALS AND METHODS
Data Source and Study Population
We selected the 1159 hospitals with Commission on Cancer-accredited cancer programs that reported having treated thy-
roid cancer to the National Cancer Database (NCDB), a joint project of the American College of Surgeons and the
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American Cancer Society, in at least 4 of the 5 years
between 2004 and 2008. We excluded the 235 hospitals
that treated fewer than 6 thyroid cancer patients a year.
We divided the remaining hospitals by quartiles of hospi-
tal case volume and then by quartiles of RAI use. We ran-
domly sampled 589 hospitals across these quartiles. Then,
we contacted the hospital registrars and searched hospital
web sites to identify the surgeons who performed the ma-
jority of thyroid surgeries at each hospital. We identified
850 thyroid surgeons.
We used a modified Dillman method of survey
administration14 when surveying the 850 surgeons. This
method consists of 3 waves of mailings with a gift
included with the first mailing.
Survey data were deidentified, scanned, and con-
firmed. The surgeon survey responses were linked to details
on hospital case volume and hospital use of RAI from the
NCDB, which captures close to 85% of all thyroid cancer
cases in the United States.15 When treatment postsurgery
does not occur at the specified hospital, the hospital registrar
is responsible for documenting the remainder of the
patients’ disease course and treatment.16 Because patients do
not typically receive RAI after undergoing thyroid lobec-
tomy, and because RAI is not recommended in the treat-
ment of medullary or anaplastic cancer, we selected hospital
treatment with RAI in patients who underwent total thy-
roidectomy and had American Joint Committee on Cancer
stage I, well differentiated thyroid cancer (papillary, follicu-
lar, andHurthle cell types).
All surveys were deidentified, as described above,
and data were analyzed in summary form only. Exemp-
tion was granted by the University of Michigan Institu-
tional Review Board.
Measures
The survey was designed to collect key information about
thyroid cancer management through use of clinical
vignettes and survey questions (including 5-point and
6-point Likert scales). Before survey administration, we
piloted our survey instrument in a diverse group of
surgeons.
The dependent variable, use of RAI in stage I thy-
roid cancer, and 1 independent variable, hospital case vol-
ume, were obtained from the NCDB. There were 4
categories for hospital case volume: low (7-11 thyroid can-
cer cases per year), low-moderate (12-19 thyroid cancer
cases per year), moderate (20-34 thyroid cancer cases per
year), and high (35 thyroid cancer cases per year). The
data from the NCDB were then linked to the deidentified
surgeon surveys affiliated with the specified hospitals. The
remaining independent variables (number of providers
involved in decision making, number of providers admin-
istering RAI, access to a tumor board, frequency of tumor
board meetings, same-day visits with other providers, pri-
mary decision maker on RAI use, primary decision maker
on RAI dose, primary provider to administer RAI, sur-
geon involvement in decision making) were obtained
from surgeon surveys, as indicated in Figure 1. Because
surgeons could choose more than 1 practice setting, when
more than 1 practice setting was selected, we applied an
algorithm previously described by Alderman et al.17 If
they selected an academic tertiary care center (even if they
also selected a community affiliate or private practice),
then the assigned practice setting was academic. If
they chose both community-based academic affiliate and
private practice, then the assigned practice setting was
community.
Statistical Analyses
Whenmore than 1 surgeon responded from the same hos-
pital, the surgeon responses were weighted according to
the reported case volume. Surgeon case volume was cate-
gorized as 1, 5, 25, 50, 100 using the lower limits of the
corresponding response intervals to a survey item that spe-
cifically asked how many patients with thyroid cancer the
surgeon operated on in 1 year (for the 0-4 interval, the
surgeon was assigned a value of 1).
We evaluated the hospital-level use of RAI across all
independent variables. We then included the decision-mak-
ing variables that were significant on univariate analysis in a
multivariable regressionmodel adjusted for hospital case vol-
ume and surgeon-reported practice setting (academic terti-
ary care, community-based academic affiliate, and private
practice). Two-way interactions were evaluated.
We also determined the distribution of patients
according to tumor size (1.0 cm, 1.1-2.0 cm, 2.1-4.0
cm, and >4.0 cm) and lymph node status (N0, N1, NX)
within the hospitals based on the 3 categories of physician
decision makers (surgeon, endocrinologist, and nuclear
medicine/radiology/other), access to a tumor board, and
number of providers administering RAI.
All statistical tests were performed using the SAS sta-
tistical software package (version 9.2; SAS Institute Inc.,
Cary, NC). Two-sided tests were used, and P values< .05
were considered statistically significant.
RESULTS
Sample Characteristics
Figure 2 indicates that 46 of the 850 surgeons were ineli-
gible for the study. Of the 804 response-eligible surgeons,
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560 (70%) completed the survey. The majority of
respondents (90%) were men, and they had an average of
19  10 years in practice. Otolaryngologists (44%) were
the largest surgical specialists represented, followed by
general surgeons (39%), then endocrine surgeons (9%),
and other surgeon specialists (8%). Most surgeons (61%)
were in private practice, but 23% worked in an academic
setting, and 16% were employed by a community-based
academic affiliate.
Impact of Providers on Use of
Radioactive Iodine
Univariate analyses
The majority of surgeons (63%) reported that 2 pro-
viders were involved in the RAI decision-making process,
and 74% of surgeons reported their personal involvement,
as indicted in Table 1. Three or more providers adminis-
tered RAI at 46% of the affiliated hospitals. In univariate
analysis, there was a strong association between the
Figure 1. Some items from the surgeon survey are shown.
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number of providers administering RAI and the likeli-
hood of a patient with stage I thyroid cancer receiving
RAI at the hospital level (P < .001). Access to a tumor
board also was associated with a greater likelihood of
receiving RAI, but the frequency of the tumor board
meeting or same-day appointments with specialists from
different disciplines did not have an impact on receipt.
Endocrinologists more often were the primary decision
maker on whether or not to administer RAI (69%), but
nuclear medicine/radiology/other providers more
frequently were the primary decision makers regarding
RAI dose (54%) and most often were the providers
responsible for administering RAI (69%). Specialty of the
primary decision maker on whether or not to administer
RAI was associated with an increased likelihood that a
patient with stage I thyroid cancer would receive RAI
(P ¼ .004). If a surgeon was the primary decision maker,
then a mean of 42% of patients received RAI for stage I
disease; and, if the endocrinologist was the primary deci-
sion maker, then a mean of 45% of patients received RAI.
When a nuclear medicine provider/radiologist/other was
the primary decision maker, then the proportion was
higher, and a mean of 52% patients received RAI. There
was no significant association between the proportion of
patients receiving RAI at the hospital and the specialty of
the primary decision maker on dose or specialty of the
administering provider.
The proportion of patients within each tumor size
category (1.0 cm, 1.1-2.0 cm, 2.1-4.0 cm, and >4.0
cm) was the same when the primary decision maker was a
surgeon versus an endocrinologist versus a nuclear medi-
cine/radiology/other physician. Similarly, among the
patients affiliated with hospitals where nuclear medicine/
radiologist/other physicians were the primary decision
makers, 88% were without lymph node metastases versus
87% of the patients affiliated with hospitals where sur-
geons or endocrinologists were the primary decision mak-
ers. The distribution according to both tumor size and
lymph node status was almost identical in hospitals that
had access to a tumor board versus no access. Similarly,
there were very similar distributions according to tumor
size and lymph node status in hospitals that had 1, 2, and
3 physicians administering RAI. However, not having a
provider administer RAI at the affiliated hospital was asso-
ciated with a lower proportion of tumors 1.0 cm (20%
vs 24%) and with a higher proportion of N0 cancers
(89% vs 86%) compared with hospitals that had 3 pro-
viders administering RAI.
Multivariable analysis
In multivariable analysis, high case volume, private
practice, and access to a tumor board were associated with
a statistically greater likelihood that a patient with stage I
thyroid cancer would receive RAI (Table 2). There was
also a significant difference in the proportion of patients
that received RAI if no provider (P < .001) or 1 provider
(P ¼ .010) at the hospital administered RAI versus 3
providers administering RAI. There was no statistically
significant difference in hospital-level RAI use when 2
providers versus 3 providers administered RAI. However,
when nuclear medicine/radiology/other providers were
the primary decision makers on whether or not to admin-
ister RAI, a significantly higher proportion of patients
with stage I thyroid cancer received RAI at the hospital
than if the decision maker was a surgeon (P< .001) or an
endocrinologist (P < .001) (Table 2, Fig. 3). There was a
statistically significant interaction between the primary
decision maker and the number of providers administer-
ing RAI (P¼ .020). Having just 1 provider administering
RAI at the hospital was associated with a nuclear medi-
cine/radiologist/other provider not being the primary de-
cision maker. There was no interaction with access to a
tumor board.
DISCUSSION
The current study demonstrates heterogeneous treatment
processes in the care of patients with well differentiated
Figure 2. The sampling method and patient flow are
illustrated.
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thyroid cancer. The number and type of providers
involved in decision making varied by hospital. Control-
ling for hospital case volume and hospital type, we
observed that the specialty of the primary physician deci-
sion maker, the number of providers administering RAI,
and having access to a tumor board influenced the use of
RAI for stage I thyroid cancer.
Similar to studies in other disease states illustrating
the relation between access to care and treatment,18-21 if
there are more providers administering RAI or if there is
access to a tumor board, then the likelihood of treatment
with RAI increases. This difference is most marked when
there is not a provider at the affiliated hospital that admin-
isters RAI (29% vs 47% of patients receiving RAI; P <
.001), and it also is observed when there is only 1 adminis-
tering provider instead of 3 providers. Thus, both lack
of access and supply-demand may influence receipt of
RAI.
In the treatment of other malignancies, it is known
that cancer specialists are more likely to recommend the
treatments their specialty provides.22,23 Although the cur-
rent study is novel, because the focus is thyroid cancer
management and the details provided by surgeon surveys
are linked to hospital-level use, some of the findings paral-
lel what has been reported in other malignancies.22,23 The
majority of surgeons (69%) reported that nuclear
Table 1. Univariate Analysis of Clinician Decision Making and Radioactive Iodine Use
Variable No. of
Patients (%)
Proportion of Patients
That Received RAI at
Hospital: Mean6SD, %
P
No. of providers involved in decision making about use of RAI .201
‡3 105 (20) 47.8819
2 332 (63) 45.8621.35
1 90 (17) 42.4822.52
No. of providers administering RAI < .001
‡3 240 (46) 47.4719.21
2 143 (27) 48.7619.46
1 102 (20) 44.5525.01
0 36 (7) 29.2822.63
Access to tumor board .011
Yes 395 (71) 47.5420.50
No 158 (29) 42.5522.04
Frequency of tumor board .188
Weekly 166 (42) 49.4219.61
Twice a month 73 (19) 48.1519.14
Once a month 134 (34) 44.3122.57
Other 20 (5) 45.9120.22
Same-day visits with other providers .791
Yes 110 (20) 45.4619.66
No 446 (80) 46.0621.55
Primary decision maker on whether or not to administer RAI .004
Surgeon 87 (16) 42.2921.57
Endocrinologist 374 (69) 45.4220.37
NM/radiol/other 83 (15) 52.5023.05
Primary decision maker on dose of RAI .894
Surgeon 4 (1) 41.2218.63
Endocrinologist 232 (45) 46.2720.26
NM/radiol/other 282 (54) 46.1421.91
Primarily administers RAI .192
Surgeon 0 (0)
Endocrinologist 165 (31) 44.1821.72
NM/radiol/other 361 (69) 46.8021.22
Surgeon involved in RAI decision making .591
Yes 414 (74) 45.7321.20
No 143 (26) 46.8321.07
Abbreviations: NM, nuclear medicine provider; radiol, radiologist; RAI, radioactive iodine; SD, standard deviation.
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medicine/radiology/other providers administered RAI.
When these specialists acted as the primary decision mak-
ers with respect to the use of RAI, there was greater hospi-
tal-level use of RAI in stage I disease (52% vs 42%-45%;
P < .001). Specialty differences in administration rates
may be related to differences in training, variable adher-
ence to clinical guidelines, various views on risks/benefits,
or the influence of financial incentives. Previous studies
have demonstrated the role of financial incentives in influ-
encing cancer care.24,25
Although regional differences in physician opinion
about RAI use after total thyroidectomy were evaluated
previously,26 and variation in interspecialty opinion on
postoperative management has been noted,27 to our
knowledge, this is the first study to evaluate the character-
istics of decision making, including specialty of the pri-
mary decision maker, with respect to hospital-level RAI
use. Strengths of this study include a large sample size, a
high response rate, an exhaustive set of independent varia-
bles, and reliable information on the use of RAI at the hos-
pital level. Despite the strengths of this study, there are
limitations. First, similar to other survey studies, there is a
risk of nonresponse selection bias. Second, several of the
independent variables are based on surgeon report. How-
ever, it has been demonstrated that surgeon report is accu-
rate in terms of surgical volume,17 and surgeon self-report
is commonly used to report other cancer care proc-
esses.17,23,28,29 Finally, we cannot control for the selection
of patients to hospitals. In an attempt to assess the influ-
ence of patient selection to hospitals, we determined the
distribution of patients according to tumor size and
lymph node status. However, these measures are imper-
fect, because hospital use of imaging studies may have an
impact on the distribution of cancers based on size, and
hospital use of prophylactic lymph node dissections may
affect the proportion of patients with known lymph node
metastases.
In conclusion, although we did not specifically eval-
uate the appropriateness of using RAI, the current study
sheds light on the role of clinicians in the wide variation in
RAI use for low-risk thyroid cancer. In addition to previ-
ously described patient and hospital characteristics,5 it
appears that providers influence RAI use. The current
results also illustrate the heterogeneity of clinician deci-
sion making in thyroid cancer management, which
reflects the complexity of multidisciplinary care. This het-
erogeneity suggests that standardization of thyroid cancer
care will be challenging. These findings have implications
for targeted clinical guideline dissemination, future stud-
ies on thyroid cancer management, and, most important,
patient care.
Figure 3. The proportion of patients with American Joint
Committee on Cancer (AJCC) stage I thyroid cancer who
received radioactive iodine (RAI) is illustrated according to
the specialty of the primary decision maker. When the pri-
mary decision maker on whether or not to administer RAI
was a nuclear medicine (NM), radiology (Radiol), or other
provider, a greater proportion of patients with AJCC stage I
thyroid cancer received RAI at the hospital than if the pri-
mary decision maker was a surgeon (P < .001) or an endocri-
nologist (P < .001).
Table 2. Multivariable Analysis of Radioactive Iodine Use for
Stage I Thyroid Cancer
Variable Proportion of
Patients That
Received RAI
at Hospital:
Mean6SD, %
Multivariable
P
Hospital characteristics
Case volume
Low 40.1325.66 .002
Low-moderate 48.6321.97 .518
Moderate 44.2920.14 .075
High 48.4817.75 Ref
Practice setting
Academic 44.9117.34 Ref
Community-based
academic affiliate
44.0919.52 .715
Private 46.4822.92 .036
Decision-making process
Access to tumor board
Yes 47.5720.50 .006
No 42.5522.04 Ref
No. of providers administering RAI
‡3 47.4719.21 Ref
2 48.7619.46 .694
1 44.5525.01 .010
0 29.2822.63 < .001
Primary decision maker on whether or not to administer RAI
Surgeon 42.2921.57 < .001
Endocrinologist 45.4220.37 < .001
NM/radiol/other 52.5023.05 Ref
Abbreviations: NM, nuclear medicine provider; radiol, radiologist; RAI, radi-
oactive iodine; Ref, referent category; SD, standard deviation.
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